Andrea Antinori to Ritonavir
This is a "connection" page, showing publications Andrea Antinori has written about Ritonavir.
Connection Strength
0.378
-
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. HIV Clin Trials. 2018 08; 19(4):158-162.
Score: 0.064
-
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
Score: 0.063
-
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA =50 cp/mL. Infection. 2017 Aug; 45(4):521-528.
Score: 0.058
-
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
Score: 0.058
-
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One. 2017; 12(2):e0171611.
Score: 0.057
-
Steroid-Responsive Encephalitis in Coronavirus Disease 2019. Ann Neurol. 2020 08; 88(2):423-427.
Score: 0.018
-
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One. 2018; 13(2):e0192627.
Score: 0.015
-
Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. J Antimicrob Chemother. 2018 Jan 01; 73(1):160-164.
Score: 0.015
-
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One. 2017; 12(11):e0187393.
Score: 0.015
-
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
Score: 0.014